Viscosupplementation is a gel like fluid called hyaluronic acid which is ideally injected into the knee joint. Hyaluronic acid is a naturally occurring substance found in synovial fluid surrounding the joints. It majorly acts as lubricant to enable the bone to move smoothly over each other. The growing population with Knee Arthritis, Hip Osteoarthritis and demand for treatment like viscosupplementation is expected to drive the market growth to huge extend. Besides, the treatment helps in managing the pain, and other symptoms. The increasing healthcare expenditures for treatment across the globe is the key factor accelerating the growth of the market.
The viscosupplementation market is driven by increasing incidence of knee osteoarthritis where the population has increasing requirement for viscosupplementation which is likely to boost the growth of market. Also, integration of proprietary technology to offer significant opportunities is propelling the growth of market. Besides, growing clinical trials for new products in viscosupplementation is the key factor driving the growth of market across the globe. Also, different policies like Medicaid, medicare, private health insurance and out of pocket expenditure is likely to fuel the market growth to huge extent.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the viscosupplementation market. In addition, complete analysis of changes on the viscosupplementation market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
The viscosupplementation market comprises of different market segment like product, hyaluronic acid type, application, end-user and geography
By product, the viscosupplementation market includes key segment of single injection, three injection, and five injection. Three injection is anticipated to dominate in the global market owing to rising patient requirement for products which can help to reduce the symptoms of knee arthritis, hip osteoarthritis. The three injection are usually given according to three dose are given once in a week. Also, single injection is expected to witness the growth at highest pace during the estimated time period. Similarly growing innovation in single injection for producing new single injection is expected to fuel the demand for the market during the forecast period.
The viscosupplementation market, includes different hyaluronic acid type like stabilized hyaluronic acid, standard hyaluronic acid. Stabilized hyaluronic acid is expected to lead in the market for viscosupplementation owing to rising demand for stabilized hyaluronic acid. Also, benefits provides by segment like reducing pain and swelling is expected to propel the growth of the segment during the forecast period. Standard hyaluronic acid is likely to witness growth at moderate pace during the estimated time period. The rising new innovation, research for segment is the factor contributing in the growth of segment.
The viscosupplementation market finds its major application in knee arthritis, hip osteoarthritis and others. Knee arthritis is expected to register major market share in viscosupplementation market owing to growing burden of population with knee arthritis due to factor like age, genetics, bone density, trauma, obesity which has led the growing cases of knee arthritis across the globe. Also, rising number of sport injuries like knee from has increasing demand for the viscosupplementation market. This features of segment is expected to boost the growth of segment during the forecast period. Also, hip osteoarthritis is expected to hold second position in the market attributing to growing prevalence in elderly population and requirement for viscosupplementation has led the new growth avenue for the market worldwide.
The viscosupplementation market has different end user like hospitals, orthopedic clinics/ambulatory surgical centers (ascs). Hospitals is expected to gain major market share in the global viscosupplementation market. The growth is due to increasing patient inflow for treatment where viscosupplementation is widely used in knee arthritis, hip osteoarthritis patient. Besides, increasing spending on healthcare by population for treatment, rising awareness is likely to boost the growth of the segment. Adding to that orthopedic clinics/ambulatory surgical centers is expected to hold second position in the market owing to ability of end user for providing the treatment in one day with availability of different viscosupplementation products.
The global viscosupplementation market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW). North America is expected to lead in the global viscosupplementation market owing to increasing different knee injuries, fractures, trauma and hip injuries. Besides, growing burden of arthritis in knee and, hip osteoarthritis is accelerating the growth of the market in the region. Also, population with obesity, changing lifestyles is expected to drive the market. Additionally, presence of key manufacturer in the region and product innovation, launches is likely to contribute healthy growth in the market. Likewise, Asia Pacific is anticipated to witness the growth at highest pace during the forecast period. The increasing geriatric population, rising in disposable income, presence of different manufacturer is fuelling the growth of the market in region.
The key players in viscosupplementation market are Anika Therapeutics, Inc. , Aptissen SA , Bioventus, Singclean ,CROMA-PHARMA, Dr. Reddy's Laboratories, Ferring Pharmaceuticals, Fidia Pharma USA Inc , BioPolymer GmbH & Co. KG, Johnson & Johnson, LG Life Sciences, LABRHA International , Virchow biotech, Sun Phrama , Mylan, OrthogenRx , Roche, Ettsons , Sanofi Genzyme, Seikagaku Corporation, Smith & Nephew, Stellar Phamaceuticals Inc, Tecnofarma S.A., TRB Chemedica International, Wellchem Pharmaceuticals Pte Ltd., Zimmer Biomet
March 2021: Seikagaku Corporation announced a manufacturing and marketing approval in Japan for JOYCLU 30mg Intra-articular Injection, a Joint Function Improvement Agent, for the Indication of Osteoarthritis (Knee Joint and Hip Joint). The approval is based on the results of three Phase III clinical studies. The company demonstrated a statistically significant improvement in WOMAC pain scores over twelve weeks after the initial injection.
December 2019: Fidia pharma USA Inc. introduced TRILURON in the U.S. It is a 3 injection product for the treatment of osteoarthritis. It also completes the HA viscosupplement portfolio offering for Fidia Pharma USA Inc.
January 2019: Bioventus launched Durolane, single injection joint fluid osteoarthritis treatment in Malaysia and selected Athrotech as its exclusive distribution partner for market. Arthotech is beneficial for Bioventus as it continues to grow in Asia and expand the reach and Malaysia is the fourth market in Asia where Durolane is introduced.
May 2017: ETTSONS Medical Partner had officially announced the launch of MONOSHOT =SOLO 120. The products contains 120 mg of pure HA in 1 single injection of 4.8 ml. The product is significantly designed to treat knee OA
The report analyses the viscosupplementation market based on by product, hyaluronic acid type, application, end-user and geography. By product, the viscosupplementation market includes key segment of single injection, three injection, and five injection. Three injection is anticipated to dominate in the global market. The viscosupplementation market, includes different hyaluronic acid type like stabilized hyaluronic acid, standard hyaluronic acid. Stabilized hyaluronic acid is expected to lead in the market for viscosupplementation. The viscosupplementation market finds its major application in knee arthritis, hip osteoarthritis and others. Knee arthritis is expected to register major market share in viscosupplementation market. The viscosupplementation market has different end user like hospitals, orthopedic clinics/ambulatory surgical centers (ascs). Hospitals is expected to gain major market share in the global viscosupplementation market. The global viscosupplementation market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW).
Why to buy this report: